New Light-Based combo tackles tough lung cancers
NCT ID NCT06943664
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a new approach for advanced non-small cell lung cancer that hasn't responded to standard treatments. It combines photoimmunotherapy (ASP-1929), a light-activated drug that targets cancer cells, with cemiplimab, an immunotherapy that boosts the immune system. About 27 adults with stage IIIB-IV lung cancer will receive both treatments to see if the combination can shrink tumors and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASP-1929 (cetuximab sarotalocan sodium) and cemiplimab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 27 participants, so results may not apply broadly. The treatment involves light activation and may cause side effects like skin reactions or immune-related issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy